• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Psyched Wellness Ltd. to Present at H.C. Wainwright Conference on June 17, 2021

Microdose by Microdose
June 10, 2021
in Press Releases
Reading Time: 3 mins read
A A

Toronto, Ontario–(Newsfile Corp. – June 10, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the Company will be participating in the upcoming H.C. Wainwright’s Psychiatry and Beyond Virtual Conference on Thursday, June 17 2021.

H.C. Wainwright – Psychedelics in Psychiatry and Beyond Virtual Conference

Date: Thursday, June 17th

Registration & Webcast: https://hcwevents.com/psychedelics/

[bsa_pro_ad_space id=2]
ADVERTISEMENT

For more information regarding these investor conferences, please visit the sponsor’s conference website above. To schedule a one-on-one meeting with management please reach out to your conference representative or the Company’s investor contact.

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com

Investor Contacts:

Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478
e: PsychedWellness@kcsa.com

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: the promotion of stress relief, relaxation and assist with restful sleeping.

Cautionary Note Regarding Forward-looking Information

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Order Lasix Today

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company’s participation in H.C. Wainwright’s Psychiatry and Beyond Virtual Conference and the timing thereof, the Company becoming a North American leader in the emerging functional mushroom food category and the Company’s goals, objectives and future business plans and products. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of or the negative of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended, including the Company not participating in H.C. Wainwright’s conference, and the inability of the Company to reach commercial production, produce products that meet its objectives and/or the inability of the Company to become a North American leader in the emerging functional mushroom food category. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Tags: Psyched Wellness
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.